1 / 5

Desmopressin: PRN Treatment in OAB

Desmopressin: PRN Treatment in OAB. Prospective, randomised, multi-centre, multinational, double-blind, placebo controlled observational study 60 women with severe daytime urinary incontinence PRN desmopressin 40 µg spray vs placebo Primary Endpoint: 4hr dry period following dosing

tallis
Download Presentation

Desmopressin: PRN Treatment in OAB

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Desmopressin: PRN Treatment in OAB • Prospective, randomised, multi-centre, multinational, double-blind, placebo controlled observational study • 60 women with severe daytime urinary incontinence • PRN desmopressin 40µg spray vs placebo • Primary Endpoint: 4hr dry period following dosing • Secondary Endpoints: time to first void / incontinence episode Voided volumes Dry periods • Patients taking desmopressin; Higher frequency of dry days Lower voided volume Longer time to first void/incontinence episode Robinson et al, 2004

  2. PRN Desmopressin: Efficacy in First 4 Hours Robinson et al, 2004

  3. Desmopressin: PRN Treatment in OAB • 37% of patients had no leakage on virtually all treatment days for 4 hours after administration • 4-8 hours: 67.8% incidence of dry periods on desmopressin Vs 62.7% on placebo • 8-24 hours: incidence of dry periods was similar • No serious adverse effects; 11% failed to complete • Desmopressinis safe and effective, allowing women to choose when they need treatment • Self-motivation allows choice; thus improving compliance Robinson et al, 2004

  4. Desmopressin: PRN Treatment in OAB • 2 week, multi-national, multi-centre, proof of concept, phase IIB, double blind, placebo controlled, prospective randomised cross over study • Men and women with OAB • Inclusion: • ≥4 voids in the first 8 hrs after rising • Oral Desmopressin 0.2mg Vs Placebo • Primary endpoint; Effectiveness of desmopressin in increasing the time to first OAB symptom episodes during 8 hrs post dose Hashim et al, 2009

  5. Desmopressin: PRN Treatment in OAB • Time to 1st void 8 min later on desmopressin (p=0.27) • Desmopressin; One less void per 8hrs (3.2 vs 4.2) (p<0.001) Increase in time to first urgency episode (p<0.003) Decrease in urgency episodes (p<0.003) • Subjective improvement in frequency and urgency • Improvement in QoL using ICIQ-OAB • Adverse events reported as mild, no hyponatremia • Novel, feasible and safe short term treatment for OAB Hashim et al, 2009

More Related